Our Firm is looking forward to the upcoming Risperdal meeting in the Philadelphia Court of Common Pleas, as we are actively filing claims in this jurisdiction.
New York, NY (PRWEB) December 12, 2014
A meeting to discuss Risperdal lawsuits (http://www.risperdallawsuit2015.com/) is scheduled to take place next month in the Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports.
According to a Calendar posted on the Pennsylvania state court’s website, the consolidated litigation’s next status conference will take place on January 12, 2015 at 2:00 p.m., at which time its parties will likely address matters related to cases involving the antipsychotic medication. Risperdal lawsuits filed in the proceeding allege symptoms associated with gynecomastia, a condition referring to male breast growth, and other complications allegedly caused by the drug. Plaintiffs in these cases accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of failing to adequately warn patients about the risks associated with its product, which they claim to have been designed defectively. (In Re: Risperdal Litigation, Case Number 100300296).
“Our Firm is looking forward to the upcoming Risperdal meeting in the Philadelphia Court of Common Pleas, as we are actively filing claims in this jurisdiction,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm is actively evaluating potential Risperdal lawsuits on behalf of men and young boys who allegedly developed gynecomastia after taking the antipsychotic medication.
According to court records updated recently, more than 1,130 Risperdal lawsuits are now pending in the Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All cases filed by the Firm allege symptoms associated with gynecomastia, which may include swollen or painful breasts, lactation, diagnosis of gynecomastia and/or surgical treatment of the condition. Plaintiffs in Risperdal lawsuits allege that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, failed to warn doctors and patients about the medication’s potential to cause the body to produce elevated levels of a hormone normally associated with lactation and female breast growth. Plaintiffs further allege that the companies promoted Risperdal for off-label pediatric uses, including the treatment of children before it received federal approval for such purposes in 2006.
Johnson & Johnson and Janssen’s marketing practices involving Risperdal have also been called into question by the federal government, who accused the companies of misbranding the medication to elderly patients with dementia, and for pediatric uses.
In November 2013, they agreed to pay approximately $2.2 billion to resolve the claims, which equated to one of the largest healthcare fraud settlements in history, according to the U.S. Department of Justice. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Risperdal is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) to treat bipolar disorder and schizophrenia in adults and adolescents, as well as symptoms of irritability in children 5-to-16 years old with autism.
The medication has also been prescribed frequently to children with ADHD, despite its lack of approval for this use.*
Men and young boys who allegedly developed gynecomastia caused by Risperdal may be eligible to receive compensation for medical bills, lost wages, pain and suffering and other injury-related damages. Learn more about Risperdal’s alleged association with gynecomastia by visiting Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com